Vanguard C3 Injectable Live Vaccine for Dogs

Land: Australia

Språk: engelsk

Kilde: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Aktiv ingrediens:

CANINE DISTEMPER VIRUS, STRAIN N-CDV; CANINE ADENOVIRUS TYPE 2, STRAIN MANHATTAN; CANINE PARVOVIRUS, STRAIN NL-35-D; GENTAMICIN

Tilgjengelig fra:

ZOETIS AUSTRALIA PTY LTD

Legemiddelform:

MISC. VACCINES OR ANTI SERA

Sammensetning:

CANINE DISTEMPER VIRUS, STRAIN N-CDV VACCINE-VIRAL Active 0.0 P; CANINE ADENOVIRUS TYPE 2, STRAIN MANHATTAN VACCINE-VIRAL Active 0.0 P; CANINE PARVOVIRUS, STRAIN NL-35-D VACCINE-VIRAL Active 0.0 P; GENTAMICIN ANTIBIOTIC Other 30.0 ug/ml

Enheter i pakken:

25 x 1 dose vial; 25 x 1 dose vial, 25 x 1 mL vial sterile diluent.

Klasse:

VM - Veterinary Medicine

Terapeutisk område:

IMMUNOTHERAPY

Produkt oppsummering:

Poison schedule: 4; Withholding period: ; Host/pest details: DOG - OVER 6 WEEKS OLD: [CANINE ADENOVIRUS - TYPE 1, CANINE ADENOVIRUS - TYPE 2, CANINE DISTEMPER VIRUS, CANINE PARVOVIRUS]

Autorisasjon status:

Registered

Autorisasjon dato:

2023-07-01

Informasjon til brukeren

Vanguard C3 Injectable
Live
Vaccine for Dogs
92000/134131
Product Name:
APVMA Approval No:
Label Name:
Vanguard C3 Injectable
Live
Vaccine for Dogs
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each dose contains live attenuated:
Canine distemper virus (≥ 10^2.2 TCID50)
Canine adenovirus type 2 (≥ 10^2.7 TCID50)
Canine parvovirus (≥10^6.7 TCID50)
Also contains: ≤ 30 µg gentamicin
Claims:
For use only by or under supervision of a veterinarian.
For vaccination of healthy dogs 6 weeks of age or older as an aid in
preventing canine
distemper caused by canine distemper (CD) virus, infectious canine
hepatitis (ICH) caused
by canine adenovirus type 1 (CAV-1), respiratory disease caused by
canine adenovirus
type 2 (CAV-2), and canine parvoviral enteritis caused by canine
parvovirus (CPV).
Vanguard C3 provides cross-protection against canine parvovirus
subtypes CPV-2a,
CPV-2b and CPV-2c and induces virus neutralising antibodies against
Australian strains of
these three subtypes.
Net Contents:
25 x 1 dose vial
25 x 1 dose vial, 25 x 1 mL vial sterile diluent
Directions for Use:
Restraints:
Contraindications:
Precautions:
Safety of VANGUARD C3 has not been demonstrated in reproducing and
lactating dogs. RLP APPROVED
Side Effects:
Systemic allergic reactions such as anaphylaxis may occur after use
and may require
appropriate treatment. Some animals may show systemic hypersensitivity
reactions, mainly
characterised by facial oedema and urticaria. Some animals may show
transient post-
vaccination reactions including injection site pain, lethargy,
diarrhoea and/or vomiting.
Dosage and
Administration:
Use reconstituted vaccine immediately.
For subcutaneous use only.
Only healthy animals should be vaccinated.
Preparation of vaccine:
Aseptically reconstitute the VANGUARD C3 freeze-dried vaccine with
sterile water for
injection (1 mL) or VANGUARD CCi and administer the 1 mL dose
subcutaneously.
The contents of one reconstituted vial of vaccine wi